Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Heineman

Urology Newport, RI Medical Doctor

NPI 1154394096 CMS profile 97176

38 Powel Ave, Newport, RI 02840

Open in the dashboard

General payments

$5,278

157 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Heineman of Newport, RI is reported in the CMS Open Payments database as having received $5,278 across 157 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $939 16
2024 General $292 3
2023 General $345 2
2022 General $524 5
2021 General $898 28
2020 General $937 38
2019 General $1,343 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Heineman
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Joseph Heineman were reported at $939. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Joseph Heineman Urology median Middle half National median
2019 $1,343 $480 $147–$1,201 $163
2020 $937 $246 $87–$645 $114
2021 $898 $358 $111–$1,000 $132
2022 $524 $476 $143–$1,263 $149
2023 $345 $560 $168–$1,461 $160
2024 $292 $563 $170–$1,464 $164
2025 $939 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $1,258 44 payments
  2. Urogen Pharma, Inc. $574 6 payments
  3. PROCEPT BioRobotics Corporation $317 1 payment
  4. Pfizer Inc. $300 20 payments
  5. Teleflex LLC $297 3 payments
  6. AstraZeneca Pharmaceuticals LP $231 3 payments
  7. Endo Pharmaceuticals Inc. $228 13 payments
  8. Boston Scientific Corporation $208 3 payments
  9. Ferring Pharmaceuticals Inc. $190 4 payments
  10. Sumitomo Pharma America, Inc. $184 9 payments
  11. Other $1,490 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,708 151 payments
  2. Education $570 6 payments
Products named General payments · program years 2019–2025
  1. XTANDI $862 52 payments
  2. MYRBETRIQ $484 27 payments
  3. JELMYTO $411 3 payments
  4. AQUABEAM ROBOTIC SYSTEM $317 1 payment
  5. LYNPARZA $231 3 payments
  6. AVEED $228 13 payments
  7. XIAFLEX $228 13 payments
  8. EDEX $228 13 payments
  9. GEMTESA $184 9 payments
  10. ANKTIVA $174 1 payment
  11. Other $1,948 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,541

Median for Urology: 1,053

Drug cost

$159,179

Median for Urology: $101,464

Branded share of claims

31.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 91 $75,059
Myrbetriq Mirabegron Brand 93 $54,858
Tamsulosin Hcl Generic 389 $6,366
Finasteride Generic 396 $6,098
Alfuzosin Hcl Er Alfuzosin Hcl Brand 147 $3,435
Solifenacin Succinate Generic 27 $2,891
Methenamine Hippurate Generic 41 $2,832
Oxybutynin Chloride Er Oxybutynin Chloride Brand 46 $1,362
Dutasteride Generic 24 $1,109
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 21 $952

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$115,051

Medicare's payments for the services billed

Medicare patients

532

Average age 76

Services billed

2,012

89 women, 443 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 33%
Cancer 30%
Diabetes 24%
Atrial fibrillation 23%
Chronic kidney disease 23%
Depression 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record